Takeda Pharmaceutical Company Limited (TAK)
After hours:
| Previous close | 14.06 |
| Open | 13.95 |
| Bid | 13.86 x 4000 |
| Ask | 14.00 x 4000 |
| Day's range | 13.85 - 14.02 |
| 52-week range | 13.05 - 17.31 |
| Volume | |
| Avg. volume | 2,702,567 |
| Market cap | 43.041B |
| Beta (5Y monthly) | 0.90 |
| PE ratio (TTM) | 25.67 |
| EPS (TTM) | 0.54 |
| Earnings date | N/A |
| Forward dividend & yield | 0.80 (5.71%) |
| Ex-dividend date | 29 Sept 2021 |
| 1y target est | 19.22 |
- Business Wire
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
OSAKA, Japan & PASADENA, Calif., June 27, 2022--Results from Phase 2 Study of fazirsiran in patients with alpha-1 antitrypsin deficiency published in New England Journal of Medicine.
- Business Wire
Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
CAMBRIDGE, Mass., June 22, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that it has signed a 15-year lease with BioMed Realty for approximately 600,000 square feet of research and development (R&D) and office space to be built at 585 Third Street in Kendall Square. The state-of-the-art facility will allow Takeda, the largest life sciences employer in Massachusetts, to create a purpose-built R&D facility with laboratories of the future featuring modern design elements and upgraded technology
- Motley Fool
Want Loads of Passive Income? Avoid These 3 (Very) Tempting Mistakes
Dividend stocks are just as prone as other stocks to underperforming the market and doing pretty much everything except what you want them to do -- increase and pay out. The catch is that some of the worst dividend investing mistakes are disguised as being juicy opportunities. Let's go over three of the most tempting and most destructive foibles so that you'll be protected against them when you're figuring out which passive income stocks are worth your money.
